MarketPeel
Insider Trading Intelligence
Pricing
…
TC

Terrance P. Coyne

RPRX
EVP & CFO · ROYALTY PHARMA PLC · CIK 0001814876
FILING MIX · LIFETIME27%/73%
BUYS
19
SELLS
52
TOTAL VALUE
$52.47M
COMPANIES
1
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
0
AVG SELL PX
$42.44
TRADE KIND
SHOWING 71 / 71
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
45 backtested trades · 8 horizons · 86 pending
Forward-return performance of every backtestable P/S trade by Terrance P. Coyne, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d45+33.33%+1.13%+0.61%+0.52%+0.46%1.20
14d45+31.11%+1.73%+1.37%+0.37%-0.30%0.48
30d45+40.00%+1.92%+1.64%-0.05%-3.03%-0.04
60d45+15.56%+5.35%+1.96%+2.56%-0.78%1.32
90d45(2 pending)+25.58%+9.19%+4.81%+3.31%+10.00%1.19
180d45(20 pending)+44.00%+11.98%+13.41%-8.45%-25.38%—
1y45(32 pending)+84.62%-16.94%+19.37%-36.31%-35.12%—
2y45(32 pending)+69.23%-16.04%+26.10%-42.14%-28.44%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RPRX · 0 shares · as of May 26, 2026
0451,819903,6391,355,4581,807,277202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 19 buys / 52 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
64,399$53.98$3.48M0May 26, 2026May 28, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
24,263——64,399May 6, 2026May 8, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
1,875$49.78$93.3K40,136Apr 28, 2026Apr 30, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
32,916$49.78$1.64M0Apr 28, 2026Apr 30, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
32,916$48.33$1.59M32,916Apr 1, 2026Apr 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
1,875$48.33$90.6K42,011Apr 1, 2026Apr 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
1,875$45.53$85.4K43,886Mar 23, 2026Mar 25, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
32,916$45.53$1.50M65,832Mar 23, 2026Mar 25, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
1,292$46.67$60.3K46,344Mar 2, 2026Mar 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
10,429$47.01$490.3K98,748Mar 2, 2026Mar 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
583$47.01$27.4K45,761Mar 2, 2026Mar 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
22,487$46.67$1.05M109,177Mar 2, 2026Mar 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
1,875$45.32$85.0K47,636Feb 23, 2026Feb 25, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
32,916$45.32$1.49M131,664Feb 23, 2026Feb 25, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
26,626——49,511Feb 11, 2026Feb 13, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
1,087$43.29$47.1K22,885Feb 4, 2026Feb 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
19,076$43.29$825.9K164,580Feb 4, 2026Feb 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
6,195$42.84$265.4K23,972Feb 3, 2026Feb 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
108,759$42.84$4.66M183,656Feb 3, 2026Feb 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
5,843$42.08$245.9K30,167Feb 2, 2026Feb 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
102,581$42.08$4.32M292,415Feb 2, 2026Feb 4, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
3,750$39.35$147.6K36,010Jan 20, 2026Jan 23, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
65,832$39.35$2.59M394,996Jan 20, 2026Jan 23, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
65,832$38.42$2.53M460,828Jan 2, 2026Jan 6, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
3,750$38.42$144.1K39,760Jan 2, 2026Jan 6, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
65,832$38.36$2.53M526,660Dec 15, 2025Dec 17, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
3,750$38.36$143.9K43,510Dec 15, 2025Dec 17, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
65,832$39.87$2.62M592,492Dec 1, 2025Dec 3, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
3,750$39.87$149.5K47,260Dec 1, 2025Dec 3, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
3,126$38.67$120.9K51,634Nov 24, 2025Nov 26, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
624$37.96$23.7K51,010Nov 24, 2025Nov 26, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
55,146$38.67$2.13M669,010Nov 24, 2025Nov 26, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
10,686$37.96$405.6K658,324Nov 24, 2025Nov 26, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
65,844$39.30$2.59M724,156Nov 17, 2025Nov 19, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
3,750$39.30$147.4K54,760Nov 17, 2025Nov 19, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
6,168——58,510Nov 5, 2025Nov 7, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALEGRANT
Gift
1,000——43,350Aug 8, 2025Aug 8, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
3,696——52,342Aug 6, 2025Aug 8, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
1,807,277——1,807,277May 16, 2025May 20, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
48,646——48,646May 8, 2025May 9, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALEGRANT
Gift
2,000——44,350Aug 12, 2024Aug 12, 2024 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
37,500$30.75$1.15M790,000Aug 10, 2023Aug 11, 2023 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
37,500$30.72$1.15M827,500Aug 9, 2023Aug 11, 2023 ↗View →
RPRX
ROYALTY PHARMA PLC
SALEGRANT
Gift
1,650——46,350Aug 8, 2023Aug 8, 2023 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
24,500$43.47$1.07M940,000Nov 8, 2022Nov 10, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
5,500$43.06$236.8K964,500Nov 2, 2022Nov 4, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
30,000$43.19$1.30M970,000Aug 1, 2022Aug 3, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
100,000——22,945May 7, 2021May 11, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & CFO
1,000,000——1,000,000May 7, 2021May 11, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
29,820$43.71$1.30M270,180Mar 3, 2021Mar 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
11,001$45.86$504.5K201,456Mar 3, 2021Mar 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
57,723$45.09$2.60M212,457Mar 3, 2021Mar 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
1,456$46.83$68.2K200,000Mar 3, 2021Mar 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
5,022$47.88$240.4K300,000Mar 2, 2021Mar 4, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
94,978$46.89$4.45M305,022Mar 2, 2021Mar 4, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & CFO
99,770——99,770Dec 31, 2020Jan 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
9,977——778Dec 31, 2020Jan 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & CFO
300,230——400,000Dec 31, 2020Jan 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
30,023——376,468Dec 31, 2020Jan 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & CFO
24,170——24,170Jun 18, 2020Jan 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
2,417——188Jun 18, 2020Jan 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & CFO
1,500$28.00$42.0K1,500Jun 18, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & CFO
1,450$28.00$40.6K1,450Jun 18, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & CFO
2,327——181Jun 18, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & CFO
23,270——23,270Jun 18, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
2,605——2,605Jun 15, 2020Jan 5, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
406,491——406,491Jun 15, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
48,000——48,000Jun 15, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
2,508——2,508Jun 15, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
10,755——10,755Jun 15, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
305,000——305,000Jun 15, 2020Jun 23, 2020 ↗View →
Other insiders · RPRX
Loading peer insiders…
About this filer
CIK 0001814876
ROLE
EVP & CFO
PRIMARY
RPRX
COMPANIES
1
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001814876DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback